Tissue Repair

Tissue Repair Financial Leverage

The Financial Leverage (Equity Multiplier) of Tissue Repair (TRP.AX) as of Oct 27, 2026 is 1.18. In the previous year, Financial Leverage (Equity Multiplier) was 1.05 — a change of 12.52% (higher).

Financial Leverage

1.18

YoY

12.52%

Last updated:

Financial Leverage (Equity Multiplier) of Tissue Repair is 2026 1.18 . Financial Leverage (Equity Multiplier) of Tissue Repair was 2025 1.05 . It decreases by 12.52% higher compared to the previous year.

The Tissue Repair Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2019
6.23 AUD
Jan 1, 2020
1.33 AUD
Jan 1, 2021
1.02 AUD
Jan 1, 2022
1.02 AUD
Jan 1, 2023
1.02 AUD
Jan 1, 2024
1.07 AUD
Jan 1, 2025
1.05 AUD
Jan 1, 2026
1.18 AUD
The Tissue Repair Financial Leverage history
YEARFinancial LeverageYoY
1.18+12.52%
1.05-2.54%
1.07+5.10%
1.02+0.06%
1.02+0.22%
1.02-23.27%
1.33-78.67%
6.23—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Tissue Repair Stock analysis

What does Tissue Repair do? Tissue Repair Ltd. develops advanced wound healing products for chronic wounds and post-cosmetic procedure care. The company is in the final stages of completing its Phase II program for TR-987, a chronic wound product, and concluded Phase IIB trials on Glucoprime, a proprietary molecule. TR Pro+ is the firm's cosmeceutical post-procedure gel product used in minimally invasive cosmetic procedures, currently focused on commercialization. The company's revenue streams include product development for TR-987, Glucoprime, and TR Pro+. Tissue Repair Ltd. targets healthcare providers and cosmetic clinics as key buyers of its products. Healthcare providers use TR-987 for chronic wound management, while cosmetic clinics utilize TR Pro+ for post-procedure care. The firm's focus on commercialization of TR Pro+ indicates a direct sales approach to these segments. The company's pipeline includes TR-987, Glucoprime, and TR Pro+ as its core products. The firm's products are developed for specific medical and cosmetic segments. TR-987 addresses chronic wound healing, a significant healthcare need, while Glucoprime is a proprietary molecule with potential for further development. TR Pro+ serves the growing cosmeceutical market for post-procedure care. The company's business model relies on advancing its pipeline through clinical trials and commercializing its products to target healthcare and cosmetic markets. Tissue Repair is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Tissue Repair stock

Financial Leverage (Equity Multiplier) of Tissue Repair is 1.18 in 2026.

Financial Leverage (Equity Multiplier) of Tissue Repair changed from 1.05 to 1.18, representing a 12.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) Tissue Repair since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s Tissue Repair with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — Tissue Repair

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — Tissue Repair